Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 16, Issue 10, 1998, Pages 3316-3322

  Choy, H ^a   Akerley, W ^a   Safran, H ^a   Graziano, S ^a   Chung, C ^a   Williams, T ^a   Cole, B ^a   Kennedy, T ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; RANITIDINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RESPONSE; DRUG SCREENING; ESOPHAGITIS; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 0031726121     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.10.3316     Document Type: Article

References (42)

1. Parker SL, Tong T, Golden E, et al: Corner statistics. Cancer 47:5-27, 1997
2. Cunningham MP: Giving life to numbers. Cancer 47:3-4, 1997
3. Lee JS, Scott C, Komaki R, et al: Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation Therapy Oncology Group Protocol 91-06. J Clin Oncol 14:1055-1064, 1996
4. Dillman RO, Herndon J, Seagren SL, et al: Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of Cancer and Leukemia Group B (CALGB) S433 trial. J Natl Cancer Inst 88:1210-1215, 1996
5. Schaake-Koning C, Van Den Bogaert W, Dalesio O, et al: Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:521-530, 1992
6. Sause WT, Scott C, Taylor S, et al: Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced unresectable non-small-cell lung cancer. J Natl Cancer Inst 87:198-205, 1995
7. Dillman RO, Seagren SL, Propert KJ, et al: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323:940-945, 1990
8. Non-Small-Cell Lung Cancer Collaborative Group: Chemotherapy in non-small-cell lung cancer A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311:899-909, 1995
9. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by Taxol. Nature 277:665-667, 1979
10. Parness J, Horwitz SB: Taxol binds to polymerized tubulin. J Cell Biol 91:479-487, 1981
11. Manfredi JJ, Parness J, Horwitz SB: Taxol binds to cellular microtubules. J Cell Biol 94:688-696, 1982
12. Choy H, Rodriguez F, Koester S, et al: Investigation of Taxol as a potential radiation sensitizer. Cancer 71:3774-3778, 1993
13. Geard CR, Jones JM, Schiff PB: Taxol and radiation. J Natl Cancer Inst 15:89-94, 1993
14. Tishler R, Schiff PB, Geard C, et al: Taxol: A novel radiation sensitizer. Int J Radiat Oncol Biol Phys 22:613-617, 1992
15. Liebmann J, Cook J, Fisher J, et al: In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 86:441-446, 1994
16. Minarik L, Hall E: Taxol in combination with acute and low-dose rate irradiation. Radiat Oncol 32:124-128, 1994
17. Geard C, Jones J: Radiation and Taxol on synchronized human cervical carcinoma cells. Int J Radiat Oncol Biol Phys 99:565-569, 1994
18. Milas L, Hunter N, Kurdoglu B, et al: Apoptotic death of mitotically arrested cells in murine tumors treated with Taxol. Proc Am Assoc Cancer Res 35:314, 1994 (abstr)
19. Milas L, Hunter N, Mason K, et al: Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res 54:3506-3510. 1994
20. Choy H, Akerley W, Safran H, et al: Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol 12:2682-2686, 1984
21. Choy H, Safran H: Preliminary analysis of a phase II study of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small-cell lung cancer. Semin Oncol 22:55-57, 1995 (suppl 9)
22. Begg AC, VaderKolk PJ, Edmondt J, et al: Radiosensitization in vitro by cis-diammine (1.1-cyclobutanedicarboxyalto) platinum(II) (carboplatin, JM8) and etylnediammine malnatoplatinum(II) (JM40). Radiat Oncol 9:157-165, 1987
23. Begg AC, Stewart FA, Dewitt L, et al: Interaction between cisplatin and radiation in experimental rodent tumors and normal tissues, in Hill B, Bellamy A (eds): Antitumor Drug Radiation Interactions. Boca Raton, FL, CRC Press, 1989, pp 154-510
24. Coughlin CT, Richmond RC: Biologic and clinical developments of cisplatin combined with radiation: Concepts, utility, projections of new trials, and the emergence of carboplatin. Semin Oncol 16:31-43, 1989 (suppl 6)
25. Douple EB, Richmond RC: Platinum complexes as radiosensitizer of hypoxic mammalian cells. Br J Cancer 37:98-102, 1978
26. Douple EB, Richmond RC: Radiation sensitization of hypoxic tumor cell cis- and trans-dichlorodiarnmineplatinum (II). Int J Radiat Oncol Biol Phys 5:1369-1372, 1979
27. Douple EB, Richmond RC, O'Hara JA, et al: Carboplatin as a potentiator of radiation therapy. Cancer Treat Rep 12:111-124, 1985
28. Douple EB: Interaction between platinum coordination complexes and radiation, in Hill B, Bellamy A (eds): Interaction Between Antitumor Drugs and Radiation. Boca Raton, FL, CRC Press, 1990, pp 171-191
29. Douple EB: Platinum chemotherapy for cancer treatment, in Brooks RR (ed): Noble Metals and Biological Systems. Boca Raton, FL, CRC Press, 1993, pp 349-376
30. Schwachofer JHM, Croovmans RP: Effective in inhibition of recovery of cell survival by cisplatin and carboplatin: Influence of treatment sequence. Int J Radiat Oncol Biol Phys 20:1235-1241, 1991
31. Skov K, MacPhail S: Interaction of platinum drugs with clinically relevant X-ray doses in mammalian cells: A comparison of cisplatin, carboplatin, ipoplatin, and tetraplatin. Int J Radiat Oncol Biol Phys 20:221-225, 1991
32. Knox RJ, Friedlos F, Lydall DA, et al: Mechanism of cytotoxicity of anticancer platinum drugs: Evidence that cis-diamminedichloro-platinum (II) and cis-diammine-(1.1-cyclobutanedicarboxylato)platinum (II) differ only in the kinetics of their interaction with DNA. CancerRes 46:1972-1979, 1986
33. Micetich KC, Barnes D, Ericson LC: A comparative study of the cytotoxicity of anticancer platinum drugs: Evidence that cis-diamminedi-chloroplatinum (II) and cis-diammine-(u-cyclobutanedicarboxylato) platinum (II) differ only in the kinetics of their interaction with DNA. Cancer Res 45:4043-4047, 1985
34. Belani CP: Multimodality management of regionally advanced non-small-cell lung cancer. Semin Oncol 20:302-314, 1993
35. Clark JW, Santos-Moore AS. Choy H: Sequencing of Taxol and carboplatinum therapy. Submitted 1995 AACR Annual Meeting, vol 36, 1998, p 298
36. Bunn PA Jr, Kelly K: A phase I study of carboplatin and paclitaxel in non-small-cell lung cancer: A University of Colorado Cancer Center study. Semin Oncol 22:2-6, 1995 (suppl 9)
37. Johnson DH, Paul DM, Hande KR, et al: Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A phase II trial. J Clin Oncol 14:2054-2060, 1996
38. Langer CJ, Leighton JC, Comis RL, et al: Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response, and survival analysis. J Clin Oncol 13:1860-1870, 1995
39. Vafai D, Israel V, Zaretsky S, et al: Phase II trial of combination carboplatin and Taxol in non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14:352, 1995 (abstr 1067)
40. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
41. Furuse K, Fukuoka M, Takada H, et al: A randomized phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. Proc Am Soc Clin Oncol 16:459a, 1997 (abstr)
42. Roach M, Gandara DR, You HS, et al: Radiation pneumonitis following combined modality therapy for lung cancer: Analysis of prognostic factors. J Clin Oncol 13:2606-2612, 1995